Indeed, previous studies in patients showed efficacy of two 5-HT1A partial agonists, buspirone and tandospirone, in amelioration of SCAs pathology, including MJD [99,100]. This evidence concerns the gene HTR1A and Spinocerebellar ataxia type 3.